Clinical trial

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

NCT05983250

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2024-01-10

PhasePHASE3

Study timeline

Study start (actual)2024-01-10Date precision: day

Registry last updated2026-07-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Pulmonary Hypertensionunresolved

Interventions

TNX-103DRUG

PlaceboDRUG

Sponsors & collaborators

Tenax Therapeutics, Inc.lead sponsor

Medpace, Inc.collaborator

Northwestern Universitycollaborator

Mapped research locations

New YorkNew York, United States2 ChicagoIllinois, United States2 Los AngelesCalifornia, United States2 DallasTexas, United States2 IndianapolisIndiana, United States2 BostonMassachusetts, United States1 St LouisMissouri, United States1 AtlantaGeorgia, United States1 San FranciscoCalifornia, United States1 PittsburghPennsylvania, United States1 CincinnatiOhio, United States1 ColumbusOhio, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05983250 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.